ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study

BACKGROUND: ModraDoc006 is an oral formulation of docetaxel, which is co‐administered with the cytochrome P450 3A4 and P‐glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Weekly treatment with ModraDoc006/r had been evaluated in phase I trials in patients with different types of advanced solid tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermunt, Marit A. C., Robbrecht, Debbie G. J., Devriese, Lot A., Janssen, Julie M., Thijssen, Bas, Keessen, Marianne, van Eijk, Maarten, Kessels, Rob, Eskens, Ferry A. L. M., Beijnen, Jos H., Mehra, Niven, Bergman, Andries M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388171/
https://www.ncbi.nlm.nih.gov/pubmed/33709626
http://dx.doi.org/10.1002/cnr2.1367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388171/
https://www.ncbi.nlm.nih.gov/pubmed/33709626
http://dx.doi.org/10.1002/cnr2.1367

Ejemplares similares